After the team behind Karuna Therapeutics sold the firm in December for $14 billion, some members of that same group have started another biotechnology firm developing neuropsychiatric drugs.

Financing led by General Atlantic with participation from T. Rowe Price Associates, Foresite Capital, Invus, Goldman Sachs Alternatives, Canada Pension Plan Investment Board (CPP Investments) as well ...

That's why analysts overwhelmingly rate Nvidia a buy and the average forecast calls for Nvidia stock to climb almost 50% over the coming 12 months. Yet, this week, Seaport Global Securities stepped ...